This program is supported by an independent educational grant from MSD. This online education program is designed solely for healthcare professionals in the USA. The content is not available for HCPs in any other country.

Join PAH experts Dr. Sudarshan Rajagopal and Dr. Kelly Chin for this accredited, interactive 60-minute teaching session. Through real-world cases, faculty will expose common misconceptions that lead to suboptimal outcomes and demonstrate how guideline-directed, risk-based decision-making can meaningfully improve patient care.

Accreditation: 1.0 AMA PRA Category 1 Credit™

Session Highlights

The live virtual webinar will feature four interactive, case-based discussions, each structured around a prevalent myth in PAH management. The real-world cases highlight the underlying misconception driving suboptimal care, and guide participants through the evidence-based reasoning needed to rethink PAH care.

Myth 1: The Traditional Stepwise Approach Is Still Sufficient

Many patients continue to start on long-term monotherapy, reflecting older stepwise habits. Evidence and modern guidelines show this approach is outdated—early combination therapy and treat-to-target strategies improve outcomes.

Myth 2: Monotherapy Is Usually Enough

Initial improvement often does not equate to long-term stability. Most patients will not reach or maintain low-risk status on monotherapy alone. Dual or triple therapy—upfront or sequential—is frequently needed to achieve treatment goals.

Myth 3: A Patient Who Feels Better Is Stable

Symptom improvement can mask progression. Objective risk assessment tools (NT-proBNP, 6MWD, RV function, imaging) are essential for determining true stability and guiding therapy adjustment.

Myth 4: Escalation Can Wait Until Patients Worsen

Waiting for overt deterioration permits disease advancement. Guidelines increasingly emphasize proactive treatment intensification, allowing patients to reach and maintain low-risk status and improve long-term outcomes.

Who Should Attend?

This program is for U.S. healthcare professionals involved in PAH care, including:

Pulmonologists
Cardiologists
Internal Medicine Physicians
Nurse Practitioners & Physician Assistants
Pharmacists
Nurses and other HCPs involved in the management of PAH

Faculty

Sudarshan Rajagopal, M.D., Ph.D.

Cardiologist and physician–scientist at Duke Health with expertise in pulmonary arterial hypertension and advanced heart failure. He combines clinical care with translational research focused on pulmonary vascular biology, GPCR signaling, and novel therapeutic strategies. Dr. Rajagopal plays a leading role in multidisciplinary PAH programs and is recognized for advancing mechanism-based, patient-centered approaches to cardiovascular and pulmonary vascular disease.

Kelly Chin, M.D.

Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center and Professor of Internal Medicine. Dr. Chin is a nationally recognized authority in PAH clinical care and clinical trials, with extensive experience advancing guideline-based treatment approaches, risk assessment strategies, and therapeutic optimization.

Faculty Disclosure Statement / Conflict of Interest

AffinityCE adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to AffinityCE any financial relationship with an ineligible organisation. AffinityCE has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Accreditation

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

AffinityCE designates this live activity/Enduring Material a maximum of 1 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

AffinityCE designates this live activity a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Pharmacists

Pharmacists AffinityCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE).

Criteria for Claiming CPE Credit: Participants must have registered and attended the entire program. Attendance is monitored online for participation in the entire activity.

Participation Costs

There is no cost to participate in this program.

Requirements for Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

Launch and Expiration Date: 5 February 2026 – 5 February 2026

Estimated time to complete this activity: 60 minutes

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.

Learning objectives

Upon completion of this activity, participants should be better able to:

1. Describe the major pathophysiological pathways underlying PAH and how they inform therapeutic targets.

2. Apply current international guideline recommendations to ensure evidence-based use of approved PAH therapies.

3. Differentiate between monotherapy, dual therapy, and triple therapy approaches, highlighting their appropriate use in clinical practice.

4. Determine when and how to escalate therapy in patients with PAH, using risk stratification and clinical response to guide treatment intensification.

5. Develop personalized treatment plans that integrate guideline-directed therapy, pathway-based rationale, and patient-specific factors to optimize outcomes.

View all